Carbidopa

Global Parkinson's Disease Treatment: Market Report 2022: Market to Reach $6.7 Billion by 2027 - Levodopa / Carbidopa Segment is Projected to Record a 6.6% CAGR and Reach $2.4 Billion - ResearchAndMarkets.com

Retrieved on: 
Monday, November 21, 2022

Levodopa / Carbidopa, one of the segments analyzed in the report, is projected to record a 6.6% CAGR and reach US$2.4 Billion by the end of the analysis period.

Key Points: 
  • Levodopa / Carbidopa, one of the segments analyzed in the report, is projected to record a 6.6% CAGR and reach US$2.4 Billion by the end of the analysis period.
  • China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2027 trailing a CAGR of 8.4% over the analysis period 2020 to 2027.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$882.1 Million by the year 2027.
  • In the global MAO-Inhibitors segment, USA, Canada, Japan, China and Europe will drive the 5.6% CAGR estimated for this segment.

Kyowa Kirin Launches New Effort to Educate Patients About the Role of Adenosine in Parkinson's Disease (PD) and Treatment of "Off" Episodes with NOURIANZ® (istradefylline)

Retrieved on: 
Thursday, September 29, 2022

The most common side effects of NOURIANZ include uncontrolled movements (dyskinesia), dizziness, constipation, nausea, hallucinations, and problems sleeping (insomnia).

Key Points: 
  • The most common side effects of NOURIANZ include uncontrolled movements (dyskinesia), dizziness, constipation, nausea, hallucinations, and problems sleeping (insomnia).
  • Adenosine and dopamine are naturally occurring chemicals in the brain that normally work together in balance to control movement.
  • However, in Parkinson's disease there is too little dopamine activity and too much adenosine activity.
  • But as the disease progresses, patients can experience "off" episodes when the full effects of levodopa/carbidopa start to wear off, allowing Parkinson's symptoms to return.

SynAgile Completes Enrollment of its Phase 2 Clinical Trial of its DopaFuse Delivery System

Retrieved on: 
Thursday, September 1, 2022

SAN JOSE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- SynAgile Corporation ( www.SynAgile.com ) is pleased to announce it has completed enrollment of its clinical trial evaluating the DopaFuse Delivery System for the treatment of Parkinsons Disease (PD).

Key Points: 
  • SAN JOSE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- SynAgile Corporation ( www.SynAgile.com ) is pleased to announce it has completed enrollment of its clinical trial evaluating the DopaFuse Delivery System for the treatment of Parkinsons Disease (PD).
  • The clinical trial, called SCOL (Study of Continuous Oral Levodopa) is a Phase 2, open-label, multi-center study comparing the DopaFuse Delivery System to participants standard intermittent doses of oral levodopa.
  • Sixteen participants with PD from five sites in Spain, Luxembourg, and Italy have completed the study.
  • The DopaFuse Delivery System is a patented, intra-oral system that continuously and noninvasively delivers levodopa and carbidopa at a controlled rate for patients with PD.

Freezing of Gait Treatment Market Report 2022: Increasing Chronic Parkinson's Disease Along With Significant Admissions in the Hospitals Internationally Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, August 19, 2022

The global freezing of gait treatment market is growing effectually, expected to grow at a CAGR of 7.2%.

Key Points: 
  • The global freezing of gait treatment market is growing effectually, expected to grow at a CAGR of 7.2%.
  • FDA approval for new drugs, and promising pipeline products in the equipment and devices segment in the Parkinson's disease industry are driving the overall growth freezing of gait treatment market globally.
  • Levodopa (InbrijaT, by Acorda Therapeutics), along with carbidopa, remains the optimum standard of symptomatic treatment for (FoG) Parkinson disease orally.
  • Increasing chronic Parkinson's disease (PD) along with significant admissions in the hospitals internationally are notable factors expected for the growth of the market.

Evecxia Therapeutics Announces Issuance of US Patent Covering EVX-101 for Depression and Other CNS Disorders

Retrieved on: 
Tuesday, May 24, 2022

Evecxia Therapeutics today announced the issuance by the United States Patent and Trademark Office (USPTO) of an additional patent covering EVX-101.

Key Points: 
  • Evecxia Therapeutics today announced the issuance by the United States Patent and Trademark Office (USPTO) of an additional patent covering EVX-101.
  • The additional patent, entitled: COMPOSITIONS AND METHODS OF ENHANCING 5-HYDROXYTRYPTOPHAN BIOAVAILABILITY, U.S. Patent No.
  • Evecxia is the first company dedicated to realizing the therapeutic potential of amplifying serotonin synthesis to treat disorders of the brain.
  • Further, Evecxia is building an additional patent portfolio, to corroborate and extend the duration of patent protection for EVX-101, EVX-301, and other EVX drug candidates.

Intrance Medical Systems Completes $17 Million Series A Financing and Appoints Ed Schutter to Board of Directors

Retrieved on: 
Tuesday, January 4, 2022

Intrance Medical Systems Inc., a subsidiary of Sweden-based Intrance Holdings AB, today announced that it has completed the final round of a Series A financing, totaling USD $17 million.

Key Points: 
  • Intrance Medical Systems Inc., a subsidiary of Sweden-based Intrance Holdings AB, today announced that it has completed the final round of a Series A financing, totaling USD $17 million.
  • Internationally well renowned Scandinavian investors, Erik Selin and Rutger Arnhult, participated in the financing as anchor investors.
  • View the full release here: https://www.businesswire.com/news/home/20220104005153/en/
    In conjunction with the financing, Intrance appointed pharmaceutical industry leader Ed Schutter to the companys Board of Directors.
  • The addition of Ed to our board comes at a critical time in our companys growth.

First Patient Treated with the DopaFuse® Delivery System

Retrieved on: 
Wednesday, October 27, 2021

WILSON, Wyo., Oct. 27, 2021 (GLOBE NEWSWIRE) -- SynAgile is pleased to announce treatment of the first patient with the DopaFuse Delivery System in the SCOL (Study of Continuous Oral Levodopa) clinical trial.

Key Points: 
  • WILSON, Wyo., Oct. 27, 2021 (GLOBE NEWSWIRE) -- SynAgile is pleased to announce treatment of the first patient with the DopaFuse Delivery System in the SCOL (Study of Continuous Oral Levodopa) clinical trial.
  • The SCOL clinical trial is a Phase 2, open-label, multicenter study comparing the DopaFuse Delivery System to participants standard intermittent doses of oral levodopa for the treatment of Parkinsons disease.
  • The DopaFuse Delivery System is a novel, intra-oral system that continuously and noninvasively delivers levodopa and carbidopa at a controlled rate for patients with PD.
  • SynAgile has developed OraFuse, a proprietary drug delivery system that provides continuous drug delivery into the mouth.

Intrance Medical Systems Raises $8 Million to Support Development of Its Innovative Therapy for Advanced Parkinson’s Disease

Retrieved on: 
Monday, September 20, 2021

Funding will be used to initiate the U.S. clinical development program for its fixed-dose combination treatment of carbidopa, entacapone and levodopa for enteral infusion in advanced Parkinsons disease patients.

Key Points: 
  • Funding will be used to initiate the U.S. clinical development program for its fixed-dose combination treatment of carbidopa, entacapone and levodopa for enteral infusion in advanced Parkinsons disease patients.
  • Mr. Selins investment provides the opportunity to accelerate the clinical development program for our drug-device combination, said Ulf Rosn, Chairman of the Board and Co-founder of Intrance Medical Systems.
  • Intrance Medical Systems was established in 2018 as an independent spin-out from Sweden-based Lobsor Pharmaceuticals AB, founded by Ulf Rosn and Roger Bolsy.
  • Intrance Medical Systems, Inc is a private biopharmaceutical company focused on the development and commercialization of its lead clinical product for the treatment of advanced Parkinsons disease in the U.S., Canada, Mexico, South America, Japan and Taiwan.

Intrance Medical Systems Names Krai Chatamra, Ph.D., Vice President of Clinical Development

Retrieved on: 
Tuesday, August 17, 2021

Intrance Medical Systems, Inc., a subsidiary of Sweden-based Intrance Holdings AB, today announced the appointment of Krai Chatamra, Ph.D., to Vice President of Clinical Development.

Key Points: 
  • Intrance Medical Systems, Inc., a subsidiary of Sweden-based Intrance Holdings AB, today announced the appointment of Krai Chatamra, Ph.D., to Vice President of Clinical Development.
  • Krai brings a depth and breadth of experience and track record of success in drug development and regulatory affairs for neurological and neurodegenerative disorders, including advanced Parkinsons disease, that will be invaluable to our company, said Patrick Shea, Chief Executive Officer of Intrance Medical Systems.
  • In his role at Intrance, Dr. Chatamra will lead the clinical development efforts with a focus on the companys lead product, a fixed-dose combination treatment of levodopa, carbidopa and entacapone for enteral infusion in advanced Parkinsons disease patients.
  • Intrance Medical Systems, Inc., a subsidiary of Sweden-based Intrance Holdings AB, is a private biopharmaceutical company focused on the development and commercialization of its lead clinical product for the treatment of advanced Parkinsons disease in the U.S., Canada, Mexico, South America, Japan and Taiwan.

Celebrity Chef Zarela Martinez Partners with Acorda Therapeutics on the launch of “A Taste for Life with Zarela℠”

Retrieved on: 
Monday, April 12, 2021

b"Culinary icon Zarela Martinez and Acorda Therapeutics (NASDAQ: ACOR) have partnered to launch \xe2\x80\x9cA Taste for Life with Zarela\xe2\x80\x9d to celebrate Parkinson\xe2\x80\x99s Awareness Month.

Key Points: 
  • b"Culinary icon Zarela Martinez and Acorda Therapeutics (NASDAQ: ACOR) have partnered to launch \xe2\x80\x9cA Taste for Life with Zarela\xe2\x80\x9d to celebrate Parkinson\xe2\x80\x99s Awareness Month.
  • Since then, she\xe2\x80\x99s authored three cookbooks and hosted her own show on PBS, elevating her to celebrity status.
  • In addition to her medications, she stayed socially active and used nutrition and exercise to help control her Parkinson\xe2\x80\x99s symptoms.
  • It is a prescription medicine used for the return of Parkinson\xe2\x80\x99s symptoms (known as OFF episodes) in adults treated with carbidopa/levodopa medicine.